Geonhui Lee,Claudia Wong,Anna Cho,Junior J. West,Ashleigh J. Crawford,Gabriella C. Russo,R. Bishwa,Jung-Woo Kim,Lauren Hoffner,Cholsoon Jang,Moonjung Jung,Robert D. Leone,Κωνσταντίνος Κωνσταντόπουλος,Andrew J. Ewald,Denis Wirtz,Sangmoo Jeong
出处
期刊:Cancer Research [American Association for Cancer Research] 日期:2024-07-02卷期号:84 (17): 2820-2835被引量:4
Abstract The loss of E-cadherin, an epithelial cell adhesion molecule, has been implicated in metastasis by mediating the epithelial–mesenchymal transition, which promotes invasion and migration of cancer cells. However, recent studies have demonstrated that E-cadherin supports the survival and proliferation of metastatic cancer cells. Here, we identified a metabolic role for E-cadherin in breast cancer by upregulating the de novo serine synthesis pathway (SSP). The upregulated SSP provided metabolic precursors for biosynthesis and resistance to oxidative stress, enabling E-cadherin+ breast cancer cells to achieve faster tumor growth and enhanced metastases. Inhibition of phosphoglycerate dehydrogenase, a rate-limiting enzyme in the SSP, significantly and specifically hampered proliferation of E-cadherin+ breast cancer cells and rendered them vulnerable to oxidative stress, inhibiting their metastatic potential. These findings reveal that E-cadherin reprograms cellular metabolism, promoting tumor growth and metastasis of breast cancers. Significance: E-Cadherin promotes the progression and metastasis of breast cancer by upregulating the de novo serine synthesis pathway, offering promising targets for inhibiting tumor growth and metastasis in E-cadherin–expressing tumors.